Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

Author： Nieminen Tuomo   Käähöönen Mika   Viiri Leena E   Gröönroos Paula   Lehtimääki Terho  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.9, Iss.10, 2008-10, pp. : 1475-1486

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Editorial:primary Prevention of Coronary Heart Disease with Lipid Lowering Therapy

By Bernini F.   Paoletti R.  

Pharmacological Research, Vol. 35, Iss. 3, 1997-03 ,pp. : 167-167

Academic Press

Access to resources Recommend Favorite

The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease

By Sun Yan-Ming   Wang Lan-Feng   Li Jia   Li Zhu-Qin   Pan Wei  

European Journal of Clinical Pharmacology, Vol. 65, Iss. 2, 2009-02 ,pp. : 157-161

Springer Publishing Company

Access to resources Recommend Favorite

Lipid-Lowering Therapy for the Primary Prevention of Cardiovascular Disease in the Elderly: Opportunities and Challenges

By Robinson Jennifer G.  

Drugs & Aging, Vol. 26, Iss. 11, 2009-11 ,pp. : 917-931

Adis International

Access to resources Recommend Favorite

Lipid-lowering therapy in acute coronary syndromes

By  

Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US

By Rosen Virginia M.  

PharmacoEconomics, Vol. 28, Iss. 1, 2010-01 ,pp. : 47-60

Adis International

Access to resources Recommend Favorite